FDA Approves Genentech’s Rozlytrek (entrectinib) for ROS1 Non-Small Cell Lung Cancer (NSCLC) and NTRK-Driven Tumors
August 16, 2019
On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor that is NTRK fusion-positive, following progression on other therapies. This approval offers a new targeted therapy option for patients with both of these rare mutations and is only the third time that the FDA has approved a targeted therapy for any cancer with a specific mutation rather than a specific cancer type.Click here to read the full press release.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.